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Abstract Total RNA from human retlculocytes was purified 
and reverse-transcribed into cDNA using an oligodT primer. 
This cDNA was used as a template for a polymerase chain 
reaction @‘CR) with a primer specific for the N-terminal 
sequence of mammalian metallothloneius (MT) and a universal 
primer. A single amplified fragment was thus generated which 
when cloned and sequenced revealed two distinct MT cDNAs of 
almost identical molecular weights. One sequence was identical 
to that previously reported for human MT II and the other 
encoded a novel MT I isoform (MT IR). The DNA sequence of 
MT lR is distinct from those documented for other MT I 
isoforms. 
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1. Introduction 
Zinc is a trace element essential for the activity of numerous 
enzymes in all areas of metabolism. Zinc deficiency leads to a 
variety of features including anorexia, growth retardation, 
abnormal immune function, abnormal nitrogen metabolism, 
hypogeusia, impaired reproductive capacity and behavioural 
defects [l]. Assessment of zinc status is therefore important in 
the early diagnosis of zinc deficiency. 
Present methods for assessing zinc status include measure- 
ment of serum zinc, erythrocytes, leucocytes, urine and hair. 
However, it has been demonstrated that serum, leucocyte and 
hair zinc concentrations are affected by other conditions not 
associated with zinc depletion [2]. Leucocyte zinc does not 
consistently decrease during zinc deficiency and urinary zinc 
increases during trauma. These methods, which represent 
those presently available for assessing zinc status are not sa- 
tisfactory. 
Metallothioneins (MT) are low molecular weight, cytosolic 
proteins with high affinity for Znzt, Cu2+ and Cd’+. Func- 
tions of metallothionein include heavy metal homeostasis and 
detoxification [3]. Thirteen MT genes have been identified, 
which encode at least 10 functioning proteins [4]. MT iso- 
forms may be classified by their retention times on ion-ex- 
change columns, which is dictated by their overall charge. 
The major human MT isoforms are MT I and MT II, re- 
solved by ion-exchange by virtue of the nature of the amino 
acid at position 11. Recently described is a third charge-separ- 
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able isoform, MT 0 [5]. To date, sequence analysis has identi- 
fied only one MT II isoform, with aspartic acid at position 11. 
In humans, there are at least 10 MT I isoforms, with hetero- 
geneous peptide sequences, and having either a valine or a 
glycine at position 11 [6]. 
It has been suggested that zinc-MT I in human tissues 
constitutes a metabolic buffer pool of zinc which is less sus- 
ceptible to induction by factors other than zinc. It has been 
shown that the concentration of MT I within erythrocytes 
decreases in response to zinc but not copper deficiency [7]. 
By contrast, MT II responds to other factors such as infection 
and disease. Erythrocyte MT I concentrations, therefore, may 
be an important index of zinc status. However, the isoforms 
of MT expressed in red blood cells (RBC) is not known. In 
this study we have determined the MT I isoforms expressed in 
RBCs, using a molecular biology approach. 
2. Materials and methods 
2.1. Isolation of reticulocytes 
Reticulocytes were isolated from 15 ml of blood from a patient with 
polycythaemia vera (PCV). Platelets were removed by activation with 
ADP (Sigma, 0.5 mg ADP/ml of blood) and passage through a glass 
bead column [8]. Blood was then applied to a cellulose fibre column 
(Whatman CF-11). Blood eluting from the column, now free from 
white blood cells and platelets was centrifuged at 12OOXg, for 
5 min. The top third of the RBC pellet, enriched with the less dense 
reticulocytes, was immediately plunged into liquid nitrogen. 
2.2. Synthesis of cDNA 
Total RNA was isolated from approx. 5X log reticulocytes using 
the TRI Reagent protocol (Sigma Chemical Co., UK). To synthesise 
first strand cDNA, 1 pg total RNA was denatured by heating to 70°C 
for 3 min. To the denatured RNA was added 15 mM of dNTPs, 20 U 
of RNase inhibitor (RNAsin, Promega, UK), 50 pmol oligo(dT) 
adaptor primer (5’-CGG AGA TCT CCA ATG TGA TGG GAA 
TTC (T)l7-3’), (synthesized by Pharmacia Biotech., Sweden) and 200 
U of MMLV reverse transcriptase (Promega) in a volume of 30 ~1, 
with MMLV reverse transcriptase buffer (Promega). The mixture was 
incubated for 2 h at 42°C and the reaction stopped by heating to 65°C 
for 5 min. 
2.3. Amplification of MT cDNA 
cDNAs encoding all MT isoforms were amplified using PCR per- 
formed with a non-specific oligonucleotide primer corresponding to 
the oligo(dT) primer used in the first strand synthesis but lacking the 
oligo(dT) tail (5’-CGG AGA TCT CCA ATG TGA TGG GAA 
TTC-3’), and a specific primer encoding the N-terminal seven amino 
acids which are conserved throughout all human MTs (5’-ATG GACl 
T CCC AAC TGC TCI TG-3’), where I is inosine. The annealing 
temperature of the primer was estimated to be 5tiO”C. 
PCR amplification of ss-cDNA derived from 0.1 lg total RNA was 
performed with Taq polymerase (5 U, Thermus aquaticus strain 
YTl(l), Promega), 50 pmol of each the above primers and 0.25 
mM dNTPs (final concentration) buffered with Promega PCR storage 
buffer A (50 mM KCl, 10 mM Tris-HCI (pH 9.0), 1% Triton X-100, 
containing 1.25 mM MgC12). The PCR programme, performed on a 
Perkin Elmer DNA Thermal cycler 480 machine, consisted of 30 
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cycles of 1 mm at 95”C, 1 min at 55°C and 1 min at 72°C ending with 
a single cycle of 15 min at 72°C. 
Parallel amplifications with Vent (exo-) DNA polymerase (New 
England Biolabs. Ltd., UK) were performed using an identical PCR 
programme but within a reaction mix consisting of ss-cDNA derived 
from 0.1 pg total RNA, Vent (exo-) DNA polymerase (2 U), 50 pmol 
each of the above primers and 0.25 mM dNTPs (final concentration) 
in New England Biolabs buffer (10 mM KCl, 20 mM Tris-HCl (pH 
8.‘:) 10 mM (NH4)zS04, 2 mM MgS04 and 0.1% Triton X-100). 
2. !, Cloning and sequencing of PCR products 
MT fragments amplified by Taq polymerase were sub-cloned using 
thj: pGEM-T Vector system according to the manufacturer’s protocol 
(P,.omega, UK). MT fragments amplified by Vent (exo-) DNA poly- 
mcrase were sub-cloned by ligation into a pCR-Script SK(+) vector 
ac:ording to the manufacturer’s protocol (Stratagene Ltd., UK). Es- 
ch.!richia coli cells (strain JM109 for pGEM-T vector and MC1069 for 
pC ‘R-Script SK(+) vector) were transformed with MT-DNA-vector 
ligation products. 
Using the standard technique of insertional inactivation of plasmid 
L‘.c-2 gene, recombinant clones were identified. To confirm the pres- 
et- :e of MT DNA in recombinant clones, plasmid DNA (purified 
urlng Wizard DNA preparation system, Promega) was digested with 
th.: restriction enzyme NcoI and run on an agarose gel. Plasmid DNA 
and excised MT DNA were visualised in the gel using ethidium bro- 
m de (results not shown). Clones were sequenced by T7 sequencing 
(Pllarrnacia Biotech.) using the Sanger dideoxy method using 35S-a- 
dr\TP from denatured ds-DNA template. Multiple clones (10) were 
se! luenced in both directions. 
3. Results 
In the 15 ml of whole blood sample, approx. 10% of total 
er vthrocytes were reticulocytes. Total RNA (10 pg) was suc- 
cessfully isolated from 5 X 1 O6 reticulocytes. The integrity of 
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Fir:. 1. Electrophoretic analysis of products of MT-specific RT-PCR 
in reticulocytes. Lane 1: 1$X174 DNA/Hae III markers (Promega); 
lane 2: Taq DNA polymerase-amplified MT; lane 3: Vent (exo-) 
DNA polymerase-amplified MT; lane 5: Taq DNA polymerase-am- 
plitied MT digested with NcoI; lane 6: Vent (exo-) DNA polymer- 
ase-amplified MT digested with Ncol. Electrophoresis was carried 
ou: using a 2% agarose gel in a 1 XTBE buffer and DNA visualised 
using ethidium bromide. 
Fig. 2. Nucleotide sequences with protein translations (below) of re- 
ticulocyte MT II (A) and MT 1~ (B). PCR products generated using 
an MT-specific RT-PCR protocol were cloned and the nucleotide 
sequence of the cloned products determined using dsDNA T7 se- 
quencing. Three clones of each MT isofonn from Taq RT-PCR re- 
actions were sequenced. 
the RNA was confirmed by visualising the ribosomal RNAs 
on an ethidium bromide-stained agarose gel (results not 
shown). 
MT-specific PCR produced one major band at the predicted 
molecular weight for the coding and 3’-untranslated region of 
the MT gene, N 340 bp (Fig. 1). This MT cDNA was cloned, 
and 10 separate clones sequenced. From these sequences eight 
were identical to the sequence already reported for human 
MT II (Genbank accession number 500271, GenEMBL data- 
base, Fig. 2) whilst two clones contained a novel MT which, 
although its sequence showed a great homology to other MTs, 
was clearly unique (Fig. 2). Furthermore, sequence analysis 
showed that the novel MT contained an NcoI restriction site 
(using the Wisconsin DNA manipulation package, through 
Seqnet, Daresbury, UK), absent in the MT II cDNA sequence 
which allowed clones containing MT Ia to be easily identified. 
Digestion with NcoI enabled the ratio of MT II/MT Ia ex- 
pressed in reticulocytes to be estimated as 1 : 1. 
In order to confirm that this gene was not an artefact, the 
process was repeated by preparation of a second batch of 
total RNA, transcription into cDNA (as previously described) 
and amplification by PCR. To further ensure the authenticity 
of the novel MT Ia sequence, this second amplification pro- 
cedure utilised Vent (exo-) DNA polymerase with its intrinsic 
proof-reading activity instead of Taq DNA polymerase. This 
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Fig. 3. Alignment of the peptide sequences of human MT isoforms. 
(A) Human MT II peptide sequence derived from the reticulocyte 
cDNA sequence and that of MT II previously reported [6]. (B) Hu- 
man MT Ia peptide sequence and sequences of the other human 
MT I isoforms [6]. Where no residue is shown, sequence identity ex- 
ists with rMT II (A) and MT In (B). 
amplification produced a single band of N 340 bp which when 
digested with NcoI gave rise to two bands suggesting that a 
portion of the amplified product was the novel MT Z, gene 
(Fig. 1). This was confirmed by cloning the undigested frag- 
ment and sequencing clones which contained the NcoI site. 
These clones contained the novel MT Ia sequence. Sequencing 
three clones which did not contain an internal NcoI site, gave 
rise to the sequence of MT II (results not shown). 
The DNA sequence of the novel MT gene predicted a 
unique amino-acid sequence. The presence of a glycine at 
position 11 qualifies it as an MT I isoform (Fig. 3). This novel 
MT gene has been denoted MT ZR, and may be specific to 
RBCs. 
4. Discussion 
New members of the human MT family have been de- 
scribed with each tissue whose MT content is examined. These 
novel MTs have two things in common: localisation of their 
expression to a particular tissue, and co-expression of other 
‘ubiquitous’ MT isoforms, such as MT II. The expression 
profile of the MT family suggests that the ‘ubiquitous’ MT 
isoforms occupy a central position in cellular physiology, 
whilst the tissue-specific isoforms have precise biological func- 
tions relating to the tissue in which they are expressed. 
Of the MT isoforms expressed tissue-specifically, MT III 
has only been detected in brain tissue [9,10] and has been 
called ‘growth inhibitory factor’, low levels of which are im- 
plicated in the onset of Alzheimer’s disease. MT IV has only 
been detected in stratified squamous epithelia [l l] and is 
thought to play a unique role in its differentiation. Previously 
thought to be a foetal liver isoform, MT 0 has been detected 
in stimulated adult monocytes [5,12]. Monocytes induced with 
zinc express among others MT Io and MT 0, which in adults 
may be specific to these cells and have a role in monocyte 
activation and/or differentiation. We report here the MT 
mRNA profile of human reticulocytes - we found MT II 
and a novel MT I isoform, termed MT In. Isolation of the 
message encoding MT II was expected, as it is the predomi- 
nant isoform in most tissues. The predicted amino-acid se- 
quence of the novel MT IR found in reticulocytes bears the 
closest homology to MT Iz, and is classified as an MT I iso- 
form by virtue of the glycine residue at position 11 (Fig. 3) [S]. 
MT In has a novel serine at position 14: this serine and the 
unique order of amino acids throughout its sequence distin- 
guish MT IR from all other MT isoforms thus far identified 
(Fig. 3). 
The observations reported here raise questions concerning 
the control of MT expression and the cellular role of the novel 
MT isoform detected. It is known that RBC MT is synthe- 
sised by immature RBCs in the marrow [13,14]. Such a pro- 
tein may have a role in RBC proliferation and differentiation, 
delivering zinc to enzymes requiring it. Further experiments 
would examine the genomic locus of the MT IR gene, looking 
for control regions such as metal-responsive elements, gluco- 
corticoid-responsive elements, and the TATAA box. 
It has yet to be shown whether the measurement of reticu- 
locyte MT IR may be used as a specific and sensitive index of 
zinc status. 
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